NCT00469729

Timeline

Start date

Oct 1, 2007

Primary completion

Feb 1, 2013

Completion date

Jun 1, 2015

First posted

—

Last posted

—

Enrollment

101

Arms / groups

1 / —

Source

AACT · pre-existing

Sponsors

• TevaLead sponsor
• University of BarcelonaOverall official - principal investigator
• University of ValenciaOverall official - principal investigator
• Temple UniversityOverall official - principal investigator
• Texas Transplant InstituteOverall official - principal investigator
• Loyola UniversityOverall official - principal investigator
• Northwestern UniversityOverall official - principal investigator
• University of PittsburghOverall official - principal investigator
• University of VirginiaOverall official - principal investigator
• Tel Aviv UniversityOverall official - principal investigator
• University of California, Los AngelesOverall official - principal investigator
• Hebrew UniversityOverall official - principal investigator
• University of Rome Tor VergataOverall official - principal investigator
• Rutgers UniversityOverall official - principal investigator
• University of ColoradoOverall official - principal investigator
• University of FlorenceOverall official - principal investigator
• Technion UniversityOverall official - principal investigator
• Icahn School of Medicine at Mount SinaiOverall official - principal investigator
• Badalona Hospital Germans Trias i PujolOverall official - principal investigator
• University of California, IrvineOverall official - principal investigator

Drugs studied

• carlecortemcel-l

Indications studied

• Hodgkin Disease
• Leukemia, Lymphoid
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndromes
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid, Acute
• Hematologic Neoplasms